Klinische Studie

Nicht-interventionelle Studie für postmenop. Frauen mit HR+/HER2-lokal fortgeschrittenen/metast. Brustkrebs zur Bewertung der Effektivität des Behandlungsalgorithmus, beginnend mit Kisqali® (Ribociclib) in Kombination mit einem Aromatasehemmer (Ribanna)(RIBANNA)HR-pos, HER2-neg fortge. oder met. Brustkrebs zur Bewertung v. Behandlungen, die mit Kisqali® (Ribociclib) in Komb. mit einem Aromatasehemmer/Fulvestrant od. endokrin. Therapie oder Chemother. starten
EUDRACT-
NCTNCT06311383
DRKS-
Krankheitsentität(en) Brust
StudientypBeobachtungsstudie
Wesentliche Einschlusskriterien1. Patients with a histological diagnosis of locally advanced/metastatic HR+/HER2- breast Cancer 2. No prior systemic treatment for locally advanced/metastatic disease in the palliative setting 3. The treating physician has made the decision to treat the patient - with ribociclib in combination with an aromatase inhibitor or fulvestrant in first line, or - endocrine therapy in first line (e.g. letrozole, anastrozole, fulvestrant), or - chemotherapy in first line (e.g. taxanes, capecitabine, with or without bevacizumab) 4. Patient who initiated treatment for first line no longer than 4 weeks (28 days) prior to written informed consent for this study
Wesentliche Ausschlusskriterien1. Patients unable to provide written informed consent 2. Contra-indication according to the respective current German SmPC (“Fachinformation”), as judged by the treating physician 3. The patient is currently under active treatment in an investigational study (“klinische Prüfung” according to German drug law)
StatusStudie beendet
Ansprechpartner & KontaktCaritas-Krankenhaus St. Josef RegensburgFrauenheilkunde und Geburtshilfe Krankenhaus St JosefStudienzentrale0941 7823401fhk-studienzentrum(at)csj.de
zurück